MicroRNA-185 (miR-185)

MicroRNA-185 is a small, non-coding RNA molecule (microRNA) that regulates gene expression post-transcriptionally by binding to the 3' untranslated regions of target mRNAs, leading to their degradation or translational inhibition[2][1]. It is broadly conserved among species and involved in a wide range of biological processes, including cell proliferation, apoptosis, immune regulation, and organ development. MicroRNA-185 has been shown to modulate sensitivity to chemotherapeutic agents in gastric cancer by targeting the apoptosis repressor ARC, to regulate B cell function and antibody production (implicating it in autoimmune pathology), to contribute to cardiac protection by repressing hypertrophy and fibrosis signaling pathways, and to serve as a prognostic biomarker in conditions such as dilated cardiomyopathy and several cancers[3][4][5][1]. Therapeutic targeting of miR-185 is under evaluation for cancers, cardiovascular, and immune diseases, but clinical translation is hampered by concerns about unpredictable off-target effects and complex regulatory networks[3][4][5][2][1].

Other names

MIR185hsa-mir-185MIRN185hsa-miR-185-5phsa-miR-185-3p

Regulation of apoptosis (e.g., through targeting ARC in cancer)[4]; Modulation of chemotherapeutic sensitivity (by altering target gene expression)[4]; Suppression of pro-hypertrophic signaling in the heart (by targeting calcium signaling proteins and regulators, such as CaMKIIδ, Camk2d, Ncx1, Nfatc3, RhoA)[5][3]; Inhibition of immune-related molecules such as Bruton tyrosine kinase and EphB2 in B cells[3]